|| List of recent Diseases-related patents
| Method and ocular implant for transmission of nerve-stimulation light|
An improved prosthesis and method for stimulating vision nerves to obtain a vision sensation that is useful for the patient that has lost vision due to age-related macular degeneration (amd) and retinitis pigmentosa (rp) and other diseases. The present invention utilizes infrared light to cause action potentials in the retinal nerves similar to those which result from rods and cones stimulated by visible light in healthy retinas.
| Medically inspired tick removal instrument|
It is of utmost importance an embedded tick is removed promptly after attachment, without causing distress to prevent possible infection from harmful diseases. Problems are created when the cheliceral digits (ref #17) and barbed hypostome (ref #18) are disassociated and left within the host's dermis.
| (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability|
The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
| Compounds, methods of preparation and use thereof for treating cancer|
The present invention provides two compounds, namely compound a and b, as the potential anticancer drug, and a composition comprising said compound a and/or b for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases..
| Compositions and methods for regulation of tumor necrosis factor-alpha|
The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (taif) or interleukin-32 (il-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression..
| Protein damage in aging and age-related diseases|
The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage.
| Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses|
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
| Pharmaceutical composition for the prevention or treatment of inflammatory diseases or immune diseases containing ramalin|
The present invention relates to the novel use (anti-inflammatory activity) of ramalin isolated from the antarctic lichen ramalina terebrata, and more specifically to a pharmaceutical composition containing ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (inos) in the transcription stage to significantly inhibit the production of nitric oxide (no) that is a key mediator of inflammatory responses.
| Stable pharmaceutical composition and methods of using same|
The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.. .
| Pharmaceutical composition on the basis of nanomicelles containing epigallocatechin gallate and a method of administration thereof to treat atopic dermatitis, crohn's disease, adenomyosis, and hyperplastic diseases of the prostate gland|
The invention relates to pharmacy. It is an object of the present invention to produce nanomicellar structures containing egcg and achieving a positive result consisting in increasing bioavailability in peroral administration.
| Small molecule inhibitors of mcl-1 and the uses of thereof|
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having sulfonamido-1-hydroxynaphthalene structure which function as inhibitors of mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases..
| Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases|
The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.. .
| Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid|
The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mrna decay.. .
| 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors|
There are provided 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives which selectively inhibit the activity of poly (adp-ribose) polymerase parp-1 with respect to poly (adp-ribose) polymerase parp-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
| Chromene modulators of chemokine receptor activity|
Or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein w1, w2, w3, y, z, r2, r3, r3′ and r4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (i) are disclosed..
| Modulators of cystic fibrosis transmembrane conductance regulator vpi|
The present invention relates to modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating abc transporter mediated diseases using such modulators..
| Imidazopyridine derivatives which inhibit the secretion of gastric acid|
The present invention relates to substituted imidazo [1,2-a]pyridines of formula i where r is —ch2cooh or —cooh, which inhibits exogenously or endogenously stimulated gastric acid secretion and can be used in the prevention and treatment of gastric acid related diseases and gastrointestinal inflammatory diseases.. .
| New ccr2 receptor antagonists and uses thereof|
The present invention relates to novel antagonists for ccr2 (cc chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and copd.. .
| Compounds and compositions as selective estrogen receptor degraders|
In which n, m, x, y1, r1, r2, r3, r4 and r5 are defined in the summary of the invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity..
| Quinazoline derivatives as kinases inhibitors and methods of use thereof|
The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions..
| Therapeutic compounds and uses thereof|
Described herein are compounds of formula (i)-(iii), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
| Pyridine derivatives|
The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
| Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance|
The invention relates to a compound of formula (i), where r1, r2, r7, m, n, and l1 are as defined in claim 1, and to the methods for preparing same, to the pharmaceutical compositions containing same, and to the uses thereof in the treatment of diseases associated with insulin resistance syndrome.. .
| Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function|
A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2a inhibitor or a histone deacetylase inhibitor.. .
| Novel quinoxaline inhibitors of pi3k|
The invention provides methods that relate to a novel therapeutic strategy for the treatment of cancer and inflammatory diseases. In particular, the method comprises administration of a compound of formula i, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such compound admixed with at least one pharmaceutically acceptable excipient..
| Pyrazole carboxamides as janus kinase inhibitors|
The instant invention provides compounds of formula i which are jak inhibitors, and as such are useful for the treatment of jak-mediated diseases such as rheumatoid arthritis, asthma, copd and cancer.. .
| N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives|
The invention provides certain n-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition.
| Therapeutic compounds and uses thereof|
Described herein are compounds of formula (i) or formula (vi), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i) or formula (vi) and pharmaceutical compositions thereof that are mucus penetrating.
| 4-aminoquinazoline derivatives and uses thereof|
The present invention provides a 4-aminoquinazoline derivative having the chemical structure of the following formula, and the use thereof. It is demonstrated by the pharmacological experiment that, the compound or a salt thereof according to the present invention not only has distinct inhibitory effect on histone deacetylases, but also has stronger differentiation induction and anti-proliferative activities for certain tumor cells.
| Compositions and methods for the treatment of proliferative diseases|
The present invention relates to pharmaceutical compositions that contain pi3k inhibitors (e.g., pbka-specific inhibitors) and parp inhibitors. The invention also provides methods for the treatment of proliferative diseases such as cancer (e.g., breast cancer) by administering the composition(s) to a subject..
| Inhibitors of the renal outer medullary potassium channel|
And pharmaceutically acceptable salts thereof which are inhibitors of the renal outer medullary potassium (romk) channel (kir1.1). The compounds of formula i are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure..
| Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them|
Or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid β production, especially an effect of inhibiting bace1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins.. .
| Modulators of cystic fibrosis transmembrane conductance regulator|
The present invention relates to modulators of atp-binding cassette (“abc”) transporters or fragments thereof, including cystic fibrosis transmembrane conductance regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such cftr modulators..
| 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh|
The invention is directed to a compound of formula (i) or a pharmaceutically acceptable salt thereof, wherein r1-r6 are defined herein. The invention is also directed to compositions containing a compound of formula (i) and to the use of such compounds in the inhibition of mutant idh proteins having a neomorphic activity.
| Agents and methods for treating ischemic and other diseases|
This invention relates to methods of screening for modulators of mammalian cell injury cause by trpm7 gene and protein activity, compounds that modulate trpm7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of trpm7 gene and protein activity.. .
| Phenyl derivative|
Wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human s1p2 antagonistic activity. The compound may therefore be used as a therapeutic agent for s1p2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases..
| Carbamate/urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors|
The invention relates to compound of the formula i (i) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation and to medicaments comprising it for treating diseases connected to tehinhibition of h3 receptor.. .
| Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof|
The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection..
| Bicyclic compounds|
And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.
| Compounds for nonsense suppression, and methods for their use|
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mrna by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mrna..
| Biaryl heterocycle substituted oxazolidinone antibacterial agents|
The present invention relates to a biaryl heterocycle substituted oxazolidinone antibacterials shown by general formula (i), a pharmaceutically acceptable salt thereof, an isomer or a prodrug thereof, wherein r1, r2, r3, r4, r5, a and b are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition and a pharmaceutical formulation comprising the compound, and a use of the compound in the manufacture of a medicament for the treatment and/or prevention of infectious diseases and a use for the treatment and/or prevention of infectious diseases..
| Heterocyclic compounds for the inhibition of pask|
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting pas kinase (pask) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus..
| Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists|
The present invention relates to compounds of formula (i), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iglur receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iglur receptors.. .
| 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases|
The present invention relates to 5′-substituted nucleoside derivatives of formula (i): (i) and pharmaceutically acceptable salts thereof, wherein b, x, y, z, r1, r2, r3 and r3′ are as defined herein. The present invention also relates to compositions comprising at least one 5′-substituted nucleoside derivative, and methods of using the 5′-substituted nucleoside derivatives for treating or preventing hcv infection in a patient..
| Compositions and methods for jamm protein inhibition|
Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by jamm proteins are disclosed. The compounds and compositions inhibit the enzymatic activity of a jamm domain, including the jamm domain of the csn5 subunit of the cop9-signalsome (csn), the jamm domain of the rpn11/poh1/psmd14 subunit of the 26s proteasome, the jamm domain of amsh, the jamm domain of amsh-lp, the jamm domain of brcc36, among other jamm domains..
| Engineered polypeptides having enhanced duration of action with reduced immunogenicity|
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
| Immunogenic escherichia coli heat stable enterotoxin|
The present invention relates to methods and compositions for the treatment and prevention of diarrhea and diarrheal related diseases and disorders in both animals and humans. In some embodiments, the invention relates to the treatment of said diarrhea and diarrheal related diseases and disorders with a vaccine.
| Antimicrobial peptides for treatment of infectious diseases|
The present invention is directed to the peptides wkwlkkwik, wrkfwkylk, and rrwrvivkw and use of said peptides as therapeutic agents for the prophylaxis and/or treatment of infections, in particular bacterial and/or fungal infections and diseases caused by bacterial and/or fungal infections.. .
| Molecular profiling of tumors|
Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease..
| Methods, kits and computer program products using hepatocellular carcinoma (hcc) biomarkers|
Methods of determining the presence or risk of liver disease or other diseases in a subject include measuring a level of a saccharide selected from n-acetylneuraminic acid, n-acetylglucosamine, n-acetylgalactosamine, or a combination thereof on one or more glycosylated proteins and the total amount of alpha-fetoprotein in a biological sample from the subject. Glycosylated proteins include but are not limited to vascular endothelial growth factor, lymphatic vessel endothelial hyaluronan receptor, e-cadherin, alpha 1 acid glycoprotein, glypican-3, galectin-3, and any combination thereof.
| Mirna biomarkers of prostate disease|
This application describes mirnas that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These mirna biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer..
| Genotypes, alleles and molecular markers associated with asian soybean rust, as well as methods, processes and uses thereof|
The present invention relates to screening methods for rust resistance or tolerance, in particular, asian soybean rust (asr—phakopsora pachyrhizi). In addition, the present invention relates to the use of molecular markers for the glycine genus, in particular, for the glycine max species.
| Pesticidal composition comprising a pyridylethylbenzamide derivative and an insecticide compound|
A method for preventively or curatively combating the pests and diseases of crops by using this composition.. .
| Novel methods and formulations for orthopedic cell therapy|
Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of bmp family mambeis of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis,. .
| Use for glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medical-plant derived ligand|
The present invention relates to glycolipoprotein gintonin, isolated and identified from ginseng, as a natural medicinal-plant-derived ligand acting on lpa1 (lysophosphatidic acid; 1- or 2-acyl-sn-glycerol-3-phosphate), lpa2, lpa3, lpa4 and lpa5 receptors whose efficacy is exhibited physiologically/pharmaceutically via an interaction with subset receptors [lpa1(edg-2), lpa2(edg-4), lpa3(edg-7), lpa4, pla5] in the edg (endothelial differentiation gene) family in g protein-coupled receptors (gpcrs) present in the cell membranes of animals including humans. The gintonin of the present invention can be used to advantage in the prevention and treatment of various diseases arising from reduced calcium concentration and various physiological activities and pharmaceutical activities dependent on calcium, since the gintonin of the present invention interacts with lpa receptors so as to activate a series of signal transmission processes and temporarily induce an increase in free ca2+ in the cytoplasm, and a temporary increase in the intracellular calcium concentration gives rise to a temporary increase in the intracellular calcium concentration in various organs including, inter alia, those of the nervous system, cardiovascular system, endocrine system, reproductive system, digestive system and immune system when the lpa receptors are expressed, with physiological activity being exhibited..
| Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products|
Disclosed herein are an anti-obesity agent from natural products based on angiogenesis inhibitory actions, and an angiogenesis inhibitor or a composition for inhibiting obesity, containing at least one selected from the group consisting of psoraleae semen extract, siegesbeckiae herba extract, and corni fructus extract. Because the psoraleae semen extract, siegesbeckiae herba extract, and corni fructus extract of the present invention exhibit angiogenesis inhibitory effects and obesity inhibitory effects, they may be usefully used as an agent for prevention and treatment of angiogenesis-related diseases or obesity..
| Composition to be applied to the skin, and use thereof|
The present invention concerns a composition to be applied to the skin, which comprises a dermatologically compatible vehicle, coconut oil, hazelnut oil and/or avellana oil, and stinging nettle oil, as well as use thereof for the treatment of skin diseases.. .
| Methods and products for in vivo enzyme profiling|
The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions.
| Intravenous infusion of curcumin and a calcium channel blocker|
Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from plga nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers..
| Method of treating inflammation using human immunosuppressive protein|
A method of treating inflammation by administering a therapeutically effective amount of a human immunosuppressant protein (hisp) to a subject is presented. The inventors have discovered a novel immunosuppressive protein purified from the supernatant of hnt cell culture.
| Composition for management of periodontal disease|
The composition for management of periodontal diseases includes a gel matrix having a polymer system and a plurality of microspheres dispersed in the polymer system. The polymer system contains about one-half a dose of medicament, while the microspheres contain the remainder.
| Methods of promoting immune tolerance|
Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (ido) enzyme activity in cells.
| Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis|
The present invention relates to the total chemical synthesis of the monosaccharide 35# (r′═h), the disaccharide 36# (r′≠h; r″═h), the trisaccharide 37# (r′≠h; r″≠h; r′″≠h) and the tetrasaccharide 1# (r′≠h; r″≠h; r′″≠h) of the following general formula wherein r represents —y—nh2y represents a linker r′ is h or r″ is h or r′″ is h or of the lipopolysaccharide from neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide α-glcnac-(1→2)-α-hep-(1→3)-α-hep-(1→5)-α-kdo or the trisaccharide α-hep-(1→3)-α-hep-(1→5)-α-kdo or α-glcnac-(1→2)-α-hep-(1→3)-α-hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by neisseria meningitidis.. .
| Plant viral vaccines and therapeutics|
The invention relates to methods and related products for preventing and treating disease, based on the use of plant viral vaccines and plant viral defense strategies. The methods also involve the identification of appropriate therapeutic strategies for diseases such as cancers..
| Infectious clones of torque teno virus|
The present invention is directed to novel nucleotide and amino acid sequences of torque teno virus (“ttv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine ttv genotypes and isolates.
| Composition for prevention or treatment of ischemic cardiac disease, comprising inhibitor against age-albumin synthesis or release of mononuclear phagocyte system cells as active ingredient|
Disclosed is a pharmaceutical composition for the prevention or treatment of ischemic heart diseases, comprising as an active ingredient an inhibitor which acts to restrain mononuclear phagocyte system cells from synthesizing or releasing age-albumin, which induces the apoptosis of cardiomyocytes upon the onset of the ischemic heart disease. Also, a method is provided for screening an inhibitor against the age-albumin synthesis or release of mononuclear phagocyte system cells.
| Nkp46-mediated nk cell tuning|
The present invention relates to compounds (e.g. Antibodies) that specifically bind and inhibit nkp46.
| Antibody and antibody-containing composition|
For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom.
| Human ctla-4 antibodies and their uses|
The present invention provides novel human sequence antibodies against human ctla-4 and methods of treating human diseases, infections and other conditions using these antibodies.. .
| Scfv antibodies which pass epithelial and/or endothelial layers|
Scfv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with cdrs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scfv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scfv that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scfv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody..
| Compositions and methods for treatment of bacterial and mycobacterial infections|
A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of gram negative, gram positive and acid fast bacilli in general and tuberculosis (tb), mycobacterium avium complex (mac), and anthrax in particular.
| Lysosomal acid lipase therapy for nafld and related diseases|
The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
| Endometrial derived stem cells and their methods of use|
The present invention provides a method of making an insulin-producing cell derived from an endometrial stromal stem cell (essc). The invention includes the progeny of essc, including any cell type generated during the differentiation of essc towards cells that produce insulin and exhibit cell markers characteristic of insulin producing cells.
| Treatment using reprogrammed mature adult cells|
A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient.
| Cellular and molecular therapies|
The present invention provides, among other things, improved compositions and methods for the treatment of tissue damage (e.g., acute or chronic) and related diseases, disorders or conditions based on the use of pathfinder cells, extracellular secretomes thereof, and/or pathfinder cell-associated micrornas. In some embodiments, the present invention provides a method for treating tissue damage (e.g., acute or chronic) comprising a step of administering a population of cells to an individual suffering from a disease, disorder or condition characterized by acute damage to one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce tissue repair, regeneration, remodeling, reconstitution or differentiation.
| Compositions and methods for probiotic recolonization therapies|
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.
| Commensal bacteria as signal mediators within a mammalian host|
Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganisms to prevent or ameliorate diseases are also provided.
| Composition and methods for the treatment of degenerative retinal conditions|
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the nlrp3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation.
| Stomatological composition|
A stomatological composition is provided. The stomatological composition is capable of stably compounding an antibody obtained from a hen egg yolk, and preventing diseases in an oral cavity such as odontonecrosis and periodontal disease from occurring, or improving such diseases in the oral cavity.
| Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders|
Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, paget's disease, and bone metastases) and as imaging agents..
| Chimeric and humanized anti-histone antibodies|
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.